One of the great cancer debates right now is what to do with early stage prostate cancer. Many more of these cancers are being found because of increased screening. There’s a real question about how dangerous these cancers are and whether they should be treated. There are guidelines for active surveillance and who will do well with it, but there are also differing opinions. Choosing active surveillance means you avoid the potential side effects of treatment, including sexual and urinary problems.
About 50% of men who opt for active surveillance will have changes within five years that require active treatment, says Dr. David Brooks, Chief of Urologic Oncology at Stanford Medicine.
Learn more about SurvivorNet's rigorous medical review process.
Dr. James Brooks is a urologic oncologist at Stanford Hospital & Clinics and an associate professor in the School of Medicine. Read More
One of the great cancer debates right now is what to do with early stage prostate cancer. Many more of these cancers are being found because of increased screening. There’s a real question about how dangerous these cancers are and whether they should be treated. There are guidelines for active surveillance and who will do well with it, but there are also differing opinions. Choosing active surveillance means you avoid the potential side effects of treatment, including sexual and urinary problems.
About 50% of men who opt for active surveillance will have changes within five years that require active treatment, says Dr. David Brooks, Chief of Urologic Oncology at Stanford Medicine.
Read More
